<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1123694601002921&amp;ev=PageView&amp;noscript=1">

Medical Systems News

Taiwan's government organization decides to stockpile Fujifilm's anti-influenza drug “Avigan® Tablet” —Fujifilm supplies Avigan® Tablet to Taiwan—

FUJIFILM Corporation (President: Shigehiro Nakajima) has announced that it provided, on July 13, a shipment of the anti-influenza drug Avigan® Tablet 200mg (Favipiravir, hereinafter “Avigan Tablet”) to Taiwan's government organization in charge of infectious disease control, called the Centers for Disease Control, R.O.C. (Taiwan) (hereinafter “Taiwanese CDC”), following its decision to stockpile Avigan Tablet. The Taiwanese CDC made the decision to protect Taiwanese citizens from the risk of new strains of influenza including avian and swine influenzas due to a growing possibility of its human transmission in Taiwan. Taiwan's Food and Drug Administration has yet to approve the manufacturing and marketing of Avigan Tablet at this stage, but the Taiwanese CDC has decided the import of the experimental drug exceptionally in recognition of its new mechanism of action and other benefits.

Read More

Topics: Corporate, News Releases

Fujifilm signs an exclusive market agreement with Chinese major pharmaceutical company Shenzhen Main Luck for the distribution of its oral synthetic quinolone antibacterial agent.

FUJIFILM Corporation (President: Shigehiro Nakajima; Hereinafter “Fujifilm”) has announced that it signed an exclusive marketing agreement with China's major pharmaceutical company Shenzhen Main Luck Pharmaceuticals Inc. (President: Yuan Qing; Hereinafter “Shenzhen Main Luck”) on June 26, 2015 for the oral synthetic quinolone antibacterial agent “T-3811” (generic name: garenoxacin mesilate hydrate), developed by the Fujifilm Group company Toyama Chemical Co., Ltd(Hereinafter “Toyama Chemical”).
Fujifilm now plans to start marketing T-3811 via Shenzhen Main Luck after obtaining import drug license for the drug in China. This will be the first time for Fujifilm to market a pharmaceutical product overseas.

Read More

Topics: Corporate, News Releases

Fujifilm acquires the U.S. medical IT software company TeraMedica, Inc. to expand its healthcare IT business

FUJIFILM Corporation (President: Shigehiro Nakajima) has announced that it completed the acquisition, through the U.S. sales subsidiary FUJIFILM Medical Systems U.S.A., Inc., of the U.S. medical IT software company TeraMedica, Inc. (Milwaukee, Wisconsin; hereafter “TeraMedica”). TeraMedica offers archive solutions for managing and storing a range of digitized in-hospital clinical information*, including diagnostic images of Picture Archiving Communication System (PACS)** to movie file images. TeraMedica became a full 100% subsidiary of the FUJIFILM Group on May 11, 2015 (U.S. EDT).

Read More

Topics: Investor Relations, Corporate, News Releases

Successful closure of the TOB for Cellular Dynamics International Inc., a leading U.S. company in the development and manufacture of iPSCs

On April 3, 2015, FUJIFILM Holdings Corporation (President: Mr. Shigehiro Nakajima) (hereafter, “Fujifilm”) launched a tender offer bid (hereafter, “TOB”) offering USD 16.50 per share for the issued and outstanding shares of common stock of Cellular Dynamics International, Inc., a leading company in the development and manufacture of iPS Cells (CEO: Robert Palay, Headquarters: Madison, Wisconsin, USA, NASDAQ listed, Securities code: ICEL) (hereafter, “CDI”). The TOB period expired on April 30, 2015 at 11:59 PM (U.S. Eastern Standard Time). The TOB is now successfully completed. On May 1, 2015 (U.S. Eastern Standard Time), following the completion of the necessary procedures, CDI will become a wholly-owned subsidiary of Fujifilm.

Having Japan Tissue Engineering as its subsidiary, Fujifilm has been strengthening its competitive advantages in the area of regenerative medicines by leveraging its high performance materials and engineering capabilities. Japan Tissue Engineering is a market leader in that field and has therapeutic tissues manufacturing technologies. Fujifilm has now expanded its portfolio in this field further by welcoming CDI, a global leader in drug discovery support through iPS Cells related technologies and knowhow, into its group. Fujifilm will seek to become a global leader of regenerative medicines by concentrating technologies and know how in the expanded group.

The TOB details as below;

Read More

Topics: News Releases

Synapse MIX - Medical Imaging Excellence
Contact a Fujifilm Rep